Eventide Asset Management portfolio
Type not verifiedPortfolio as of Jun 30, 2026 (Q2 2026) · filed with the SEC on Aug 14, 2026 · data updated on Nov 5, 2026 · Q2 2026 13F (filing) ↗ · all its 13F filings ↗
A 13F shows the portfolio at quarter-end and is filed up to 45 days later: these are not real-time positions and they may have changed.
Eventide Asset Management reported a $7.5 bn portfolio of 301 positions to the SEC as of the end of Q2 2026. Its largest positions are GH, LRCX, XMTR. During the quarter it exited Prologis and Global-E Online.
Sections with a free account
What it reported after the quarter end (Q2 2026)
The 13F shows the portfolio as of Jun 30, 2026. Since then Eventide Asset Management has filed these own trades with the SEC (Form 4, when it owns more than 10% of a company or holds a role in it) and stakes above 5% (13D and 13G). It is not everything it did: only what it must report before the next 13F.
What changed this quarter
289 positions with a change (55 new, 137 added to, 63 trimmed, 34 sold); also, 2 entered through an IPO, 1 exited through an acquisition or merger, 1 entered through a spin-off. 7 are listed here: those of 0.5 points of the portfolio or more (up to 12).
- Newly listedAvalyn PharmaAVLN0.6% of the portfolio
It started trading this quarter: it appears in a 13F for the first time. The filing does not say whether the manager already held it before the listing, so it is not counted as a purchase.
- Xometry−27%fewer sharesReduced2.0% → 2.8%
- Guardant Health−17%fewer sharesReduced3.6% → 3.9%
- Prologis−0.7 ppof portfolioSold out0.9% → —
- Axsome Therapeutics−39%fewer sharesReduced1.5% → 1.0%
- Apogee Therapeutics−53%fewer sharesReduced0.8% → 0.5%
- Dell Technologies+91%more sharesIncreased0.3% → 1.1%
- Global-E Online−0.5 ppof portfolioSold out0.6% → —
The figure on the right: for positions added to or trimmed, the change in the number of shares (%); for new and sold ones, the points of the portfolio moved (pp). Below, the portfolio weight before → after. Traded weight: what it bought or sold, excluding price effects.
Top holdings
- Guardant HealthGH3.9%
- Lam ResearchLRCX3.9%
- XometryXMTR2.8%
- Trane TechnologiesTT2.7%
- Mirum PharmaceuticalsMIRM2.0%
- ASML HoldingASML1.8%
- Targa ResourcesTRGP1.8%
- Old Dominion Freight LineODFL1.7%
- GE VernovaGEV1.7%
- United RentalsURI1.6%
- ArgenxARGX1.6%
- Scholar Rock HoldingSRRK1.6%
- iRhythm HoldingsIRTC1.4%
- KLAKLAC1.3%
- Beta BionicsBBNX1.3%
Portfolio by sector
- ● Health Care 36%
- ● Information Technology 21%
- ● Industrials 21%
- ● Energy 6%
- ● Financials 5%
- ● Utilities 5%
- ● Consumer Discretionary 3%
- ● Materials 2%
- ● Real Estate 1%
Stakes above 5% (13D/13G)
Companies where this filer reported holding 5% or more of the shares. It is the figure from its latest filing on each one; history since December 2024.
How we classify it
Type not verified: we have not assigned a type because we found no document that is enough to tell. Most 13F filers are in this situation: we only review in depth those that meet the portfolio criteria.
Not counted as a concentrated manager: its portfolio is not within 5 to 100 positions; its top 10 positions are under 45%. Its portfolio is shown all the same, but it is left out of manager counts, the consensus and the ranking. How this is decided
Managers of a similar size
A 13F portfolio value between a third and three times this one, whatever the type of filer. It is not a comparison of what they hold.
- AppaloosaInvestment firm · $7.5 bn
- Peconic PartnersInvestment firm · $7.5 bn
- ACR Alpine Capital ResearchInvestment firm · $7.4 bn
- Carmignac GestionInvestment firm · $7.7 bn
- Slate Path CapitalInvestment firm · $7.2 bn
- Lyrical Asset ManagementInvestment firm · $7.9 bn